Clinical Trials Directory

Trials / Terminated

TerminatedNCT00342862

AMEVIVE® Pregnancy Registry

Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Pregnancy Exposure Registry

Status
Terminated
Phase
Study type
Observational
Enrollment
3 (actual)
Sponsor
Astellas Pharma Inc · Industry
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVE® Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses exposed to AMEVIVE® in order to detect any potential increase in the risk of major birth defects. The AMEVIVE® Pregnancy Exposure Registry is sponsored by Astellas Pharma Global Development and will be managed by INC Research. The Registry will be monitored by an independent Advisory Committee of external experts in relevant specialties of teratology, epidemiology, maternal and fetal medicine, and infectious disease medicine (external member details available upon request).

Detailed description

Prospective reports will be collected from pregnant subjects, health care provider (HCP), or Astellas Product Safety Management staff. Data from the pregnant subjects will be collected at 4 to 5 months of pregnancy by telephone interviews with the Registry. The Registry will also contact the subject at 2 months and 12 months after the estimated delivery date (EDD) for post-natal \& pediatric follow-up. The Registry will confirm the information collected from the subject with the HCP by telephone interviews with the Registry, forms mailed/faxed to the Registry, electronic forms/queries sent to the Registry, or a combination of these methods. If a live birth is reported, the infant's HCP will be contacted for the Pediatric Follow-Up at 2 months and 12 months of age. If a birth defect is reported, targeted follow-up will be conducted.

Conditions

Interventions

TypeNameDescription
DRUGAmevive exposureObservational

Timeline

Start date
2003-12-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2006-06-21
Last updated
2013-12-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00342862. Inclusion in this directory is not an endorsement.